[6-K] AC Immune SA Current Report (Foreign Issuer)

Rhea-AI Filing Summary

AC Immune SA (ACIU) filed a Form 6-K summarizing the outcomes of its 19 June 2025 Annual General Meeting (AGM). All resolutions that remained on the agenda were approved by shareholders.

• Financial statements: 2024 IFRS consolidated and statutory financial statements received shareholder approval. The company posted a CHF 45.8 million net loss, lifting accumulated losses to CHF 356.8 million.
• Compensation report: The 2024 compensation report passed on an advisory basis. Shareholders also approved maximum board compensation of CHF 1.03 million for the period AGM 2025-AGM 2026 and executive-committee compensation of CHF 7.50 million for FY 2026.
• Board changes: Four directors—Monika Bütler, Carl June, Andrea Pfeifer, Roy Twyman—were re-elected. Renée Aguiar-Lucander joined the board, while Martin Zügel was elected both director and new chair. The same individuals were confirmed for the Compensation, Nomination & Corporate Governance Committee.
• Auditor & proxy: PwC SA was re-appointed as statutory auditor for 2025; Reymond & Associés remains independent proxy through 2026.

No new financial guidance, operational updates, or transaction announcements accompanied the filing. The exhibit list references a management presentation (Ex. 99.1) not included in the text.

Positive

• All AGM resolutions approved, indicating strong shareholder support and governance stability.
• New chair (Martin Zügel) and director (Renée Aguiar-Lucander) add experience, potentially strengthening strategic oversight.

Negative

• Confirmed 2024 net loss of CHF 45.8 million increases accumulated losses to CHF 356.8 million, highlighting ongoing cash-burn concern.

Insights

Corporate Governance Expert

TL;DR: Routine AGM approvals; governance continuity with new chair, limited immediate valuation impact.

The filing reflects standard Swiss AGM business. All proposals passed comfortably, indicating continued shareholder support for management despite sizeable accumulated losses. The election of Martin Zügel as chair introduces fresh leadership but maintains board experience via multiple re-elections, reducing governance risk. Compensation caps appear aligned with prior periods, limiting dilution concerns. Re-appointment of PwC ensures audit continuity. Overall, no material change to strategic outlook or near-term cash runway is disclosed.

Portfolio Manager

TL;DR: Filing is operationally neutral; loss confirmation reminds of financing overhang.

Investors gain little incremental insight into pipeline progress or funding plans. The CHF 45.8 million 2024 loss was already public; its reiteration underscores the company’s reliance on future capital raises or partnerships. Governance approvals avert potential disruption, but do not alter the risk-reward profile tied to Alzheimer’s and neurodegeneration programs. I view the disclosure as informational, not price-moving.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2025

Commission file number: 001-37891

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

EPFL Innovation Park
Building B
1015 Lausanne, Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or
Form 40-F.

Form 20-F ☒     Form 40-F ☐

On June 19, 2025, AC Immune SA (“AC Immune”) held its Annual General Meeting of Shareholders. The final results of the voting on the agenda items are given below. The Management presentation to shareholders is attached hereto as Exhibit 99.1. Prior to the meeting, the board of directors of AC Immune withdrew agenda items 6.1 and 6.2. The final results of the remaining agenda items submitted to a vote of the shareholders are as below and the detailed results will be provided in the minutes which will be published on AC Immune’s website (https://ir.acimmune.com/governance) within 15 days:

Annual General Meeting Results

Agenda Item 1: 2024 IFRS Consolidated Financial Statements, 2024 Statutory Financial Statements, 2024 Compensation Report

Agenda Item 1.1: Approval of 2024 IFRS Consolidated Financial Statements and 2024 Statutory Financial Statements

AC Immune shareholders approved the 2024 IFRS Consolidated Financial Statements and the 2024 Statutory Financial Statements.

Agenda Item 1.2: Advisory Vote on the 2024 Compensation Report

AC Immune shareholders endorsed the 2024 Compensation Report.

Agenda Item 2: Appropriation of Losses

AC Immune shareholders approved that the net loss for the year 2024 in the amount of CHF 45,848K increases the “accumulated losses brought forward” of CHF 310,998K, resulting in a new balance of “accumulated losses brought forward” of CHF 356,846K.

Agenda Item 3: Discharge of the Members of the Board of Directors and the Executive Committee

AC Immune shareholders approved the discharge of the Members of the Board of Directors and the Executive Committee for the financial year 2024.

Agenda Item 4: Compensation for the Members of the Board of Directors and the Executive Committee

Agenda Item 4.1: Binding vote on Maximum Aggregate Compensation for Members of the Board of Directors from the AGM 2025 to the AGM 2026

AC Immune shareholders approved the total maximum amount of compensation for the Board of Directors of CHF 1,029K (excluding employer social security contributions) covering the period from the AGM 2025 to the AGM 2026.

Agenda Item 4.2: Binding vote on Maximum Aggregate Compensation for Members of the Executive Committee for the financial year 2026

AC Immune shareholders approved the total maximum compensation for the members of the Executive Committee of CHF 7,496K (excluding employer social security contributions) from 1 January 2026 to 31 December 2026.

Agenda Item 5: Re-elections and Elections

Agenda Item 5.1: Re-elections of Members of the Board of Directors

AC Immune shareholders approved the re-election of Monika Bütler, Carl June, Andrea Pfeifer, and Roy Twyman as Members of the Board of Directors, each until the end of the Annual General Meeting 2026.

Agenda Item 5.2: Elections of Members and Chair of the Board of Directors

AC Immune shareholders approved the election of Renée Aguiar-Lucander as Member of the Board and of Martin Zügel as Member and Chair of the Board.

Agenda Item 5.3: Re-election of Members of the Compensation, Nomination and Corporate Governance Committee

AC Immune shareholders approved the re-election of Monika Bütler and Roy Twyman as Members of the Compensation, Nomination and Corporate Governance Committee, each until the end of the Annual General Meeting 2026.

Agenda Item 5.4: Election of Member of the Compensation, Nomination and Corporate Governance Committee

AC Immune shareholders approved the election of Martin Zügel as Member of the Compensation, Nomination and Corporate Governance Committee until the end of the Annual General Meeting 2026.

Agenda Item 5.5: Re-election of the Statutory Auditors

AC Immune shareholders approved the re-election of PricewaterhouseCoopers SA, in Lausanne, Switzerland, as AC Immune’s statutory auditors for the financial year 2025.

Agenda Item 5.6: Re-election of the Independent Proxy

AC Immune shareholders approved the re-election of Reymond & Associés Attorneys, Lausanne, as AC Immune’s Independent proxy until the end of the Annual General Meeting 2026.

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AC IMMUNE SA
	By:	/s/ Andrea Pfeifer
		Name:	Andrea Pfeifer
		Title:	Chief Executive Officer
	By:	/s/ Christopher Roberts
		Name:	Christopher Roberts
		Title:	Chief Financial Officer

Date: June 20, 2025

EXHIBIT INDEX

Exhibit Number	Description
99.1	Annual General Meeting Presentation

FAQ

What financial statements did ACIU shareholders approve?

Investors approved the 2024 IFRS consolidated and 2024 statutory financial statements.

How much was AC Immune's 2024 net loss?

The company reported a CHF 45.8 million net loss for 2024.

Who is the new Chair of AC Immune’s Board?

Shareholders elected Martin Zügel as both director and Chair until the 2026 AGM.

What is the approved maximum executive compensation for 2026?

The AGM approved a ceiling of CHF 7.496 million (excluding social charges) for the Executive Committee.

Which audit firm will serve for FY 2025?

PricewaterhouseCoopers SA, Lausanne, was re-elected as statutory auditor.